Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07314320 · ClinicalTrials.gov registry record · Phase 1
A Study to Detect Radioactivity of [14C]-OPC-167832 in Urine and Feces in Healthy Men
A Phase 1 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT07314320 is a Phase 1 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 8 participants.
The verdict
NCT07314320, a Phase 1 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the relative amounts of radioactivity excreted in urine and feces following a single oral dose of \[14C\]-OPC-167832 in healthy male participants.
Interventions
- DRUG [14C]-OPC-167832
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-11-20 |
| Est. Completion | 2023-12-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07314320
The ClinicalTrials.gov registry entry for NCT07314320 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [14C]-OPC-167832 is the first listed.
NCT07314320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07314320 about?
NCT07314320 is a clinical study titled "A Study to Detect Radioactivity of [14C]-OPC-167832 in Urine and Feces in Healthy Men". The purpose of this study is to determine the relative amounts of radioactivity excreted in urine and feces following a single oral dose of \[14C\]-OPC-167832 in healthy male participants.
What is the current status of trial NCT07314320?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2023-11-20. Estimated completion is 2023-12-27.
What interventions are being tested in trial NCT07314320?
The interventions under investigation include: [14C]-OPC-167832 (DRUG).
Who is sponsoring clinical trial NCT07314320?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.